Obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics files for IPO

Car­mot Ther­a­peu­tics has filed to go pub­lic in a chilly en­vi­ron­ment for new list­ings, but the obe­si­ty biotech’s place in one of drug de­vel­op­ment’s hottest fields could buoy its chances of a suc­cess­ful IPO.

The Berke­ley, CA-based biotech plans to de­but on Nas­daq as $CR­MO be­fore year’s end, ac­cord­ing to a Fri­day fil­ing with the SEC.

The planned of­fer­ing comes as in­dus­try in­sid­ers say they ex­pect lit­tle IPO ac­tiv­i­ty to close out the year. In­stead, the sec­tor is like­ly to see some com­pa­nies pur­su­ing re­verse merg­ers, and oth­ers in wait-and-see un­til af­ter the JP Mor­gan health­care con­fer­ence in ear­ly Jan­u­ary

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER